Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

The nuclear factor‐κB (NF‐κB) transcription factor family has been considered the central
mediator of the inflammatory process and a key participant in innate and adaptive immune …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell non-Hodgkin lymphoma that
affects patients of all ages with a wide range of clinical presentations. Although DLBCL is …

The nuclear factor kappa B (NF-κB) family of transcription factors orchestrates signal-
induced gene expression in diverse cell types. Cellular responses to NF-κB activation are …

Immunotherapy is a promising approach for treating metastatic breast cancer (MBC), offering
new possibilities for therapy. While checkpoint inhibitors have shown great progress in the …

The NF-κB transcription factor pathway is a crucial regulator of inflammation and immune
responses. Additionally, aberrant NF-κB signaling has been identified in many types of …

The nuclear factor‐κB (NF‐κB) signaling pathway is a busy ground for the action of the
ubiquitin–proteasome system; many of the signaling steps are coordinated by protein …

Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in
inflammatory and immune responses, as well as in regulation of expression of many other …

The cellular response to survive or to undergo death is fundamental to the benefit of the
organism, and errors in this process can lead to autoimmunity and cancer. The transcription …